No black box warning on record for Iqirvo

As of the latest FDA labeling reviewed, Iqirvo (ELAFIBRANOR) does not carry a black box warning. Standard warnings and precautions still apply — see the full Iqirvo medicine page for the complete safety profile.

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Myalgia, Myopathy, and Rhabdomyolysis : Assess for muscle pain and myopathy prior to IQIRVO initiation. Consider periodic assessment (clinical exam, CPK measurement). Interrupt IQIRVO if there is new onset or worsening of muscle injury, or muscle pain. ( 5.1 ) Fractures: The risk of fracture should be considered in the care of patients treated with IQIRVO. Apply current

No black box warning on record for Iqirvo

Other warnings & precautions

5 WARNINGS AND PRECAUTIONS Myalgia, Myopathy, and Rhabdomyolysis : Assess for muscle pain and myopathy prior to IQIRVO initiation. Consider periodic assessment (clinical exam, CPK measurement). Interrupt IQIRVO if there is new onset or worsening of muscle injury, or muscle pain. ( 5.1 ) Fractures: The risk of fracture should be considered in the care of patients treated with IQIRVO. Apply current

Iqirvo Black Box Warning

No black box warning on record for Iqirvo

Other warnings & precautions

Iqirvo Black Box Warning

No black box warning on record for Iqirvo

Other warnings & precautions